New Medicare NTAP approved for InVision Precision Cardiac Amyloid — up to $2,275 per eligible inpatient stay, on top of the MS-DRG, effective October 1, 2026. Read the announcement
Blog

Notes on echo AI, evidence, and access.

Perspectives from our team on detecting under-recognized disease from routine echocardiograms — and on the clinical evidence and reimbursement that let health systems act on it.

ROUTINE ECHO VOLUME 2 FLAGGED HIGH SUSPICION
Reimbursement

Medicare's New NTAP for AI Cardiac Amyloidosis Detection: What the FY 2027 Final Rule Means for Your Hospital

CMS has approved a New Technology Add-on Payment for InVision Precision Cardiac Amyloid, effective October 1, 2026. What the final rule says, how the up-to-$2,275 add-on is calculated, and what to do before the new fiscal year.

Andrew Reeve · August 2026 · 8 min read